Q-omics provides the consensus-scored CRISP3 profile across patient tissues and cancer cell-line models. CRISP3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CRISP3 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, CRISP3 protein abundance shows 23,472 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where CRISP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRISP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRISP3 survival associations across molecular data types. CRISP3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRISP3 RNA expression–survival associations across cancer types. High CRISP3 expression shows unfavorable associations in KIRP, ACC, CHOL, MESO and SCLC, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CRISP3 RNA expression.
This table summarizes CRISP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CRISP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRISP3 shows lower tumor expression in HNSC, UCEC, LUAD, KICH and THCA and higher tumor expression in BRCA. The HNSC box plot shows higher CRISP3 RNA expression in normal versus tumor tissue (log2 FC = −6.260, t-test p < 0.001).
This table shows molecular features associated with CRISP3 in patient tissues and cancer cell lines. In patient samples, CRISP3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRISP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
